Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Company Overview - Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on addressing conditions related to the overactivity of fatty acid synthase (FASN) [3] - The company is developing a portfolio of FASN inhibitors, with its lead program being denifanstat, targeting conditions such as MASH, acne, and certain solid tumors that depend on FASN for disease progression [3] Leadership Introduction - The discussion features key executives from Sagimet, including CEO Dave Happel, SVP of New Products Rob D'Urso, Chief Medical Officer Eduardo, and Chief Financial Officer Thierry [1][2]